Guardant Health (NASDAQ:GH) Director Sells $18,148.20 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $156.45, for a total transaction of $18,148.20. Following the sale, the director directly owned 11,316 shares in the company, valued at $1,770,388.20. This trade represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, June 22nd, Musa Tariq sold 1,951 shares of Guardant Health stock. The stock was sold at an average price of $131.16, for a total value of $255,893.16.
• On Tuesday, June 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $130.19, for a total value of $15,102.04.

Guardant Health Stock Performance

Guardant Health stock opened at $167.88 on Friday. The business’s 50-day simple moving average is $153.13 and its two-hundred day simple moving average is $118.33. The company has a market cap of $22.53 billion, a PE ratio of -48.10 and a beta of 1.60. Guardant Health, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $176.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. During the same quarter in the previous year, the business earned ($0.44) earnings per share. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. World Investment Advisors acquired a new position in shares of Guardant Health during the 4th quarter worth about $1,664,000. Orbimed Advisors LLC acquired a new stake in Guardant Health in the 1st quarter worth about $40,199,000. GSA Capital Partners LLP acquired a new stake in Guardant Health in the 2nd quarter worth about $1,772,000. SWS Partners purchased a new stake in Guardant Health during the 2nd quarter worth approximately $11,190,000. Finally, Styrax Capital LP increased its stake in Guardant Health by 6.5% during the 1st quarter. Styrax Capital LP now owns 300,000 shares of the company’s stock worth $27,711,000 after buying an additional 18,411 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Mizuho upped their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. The Goldman Sachs Group reissued a “buy” rating and set a $210.00 target price on shares of Guardant Health in a report on Friday, July 31st. Morgan Stanley boosted their target price on shares of Guardant Health from $175.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Wolfe Research started coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target on the stock. Finally, TD Cowen increased their price target on Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.